A rare case of very late onset post-transplant Burkitt lymphoma

Post-transplant lymphoproliferative disorder typically manifests within the first year after solid organ transplantation, though it can rarely occur ten years or more post-transplant. Post-transplant Burkitt lymphoma is seldom seen following solid organ transplantation and represents an aggressive subtype. Treatment involves reducing immunosuppressive therapy alongside rituximab and the use of multiple chemotherapy agents.Our case involves a rare occurrence of post-transplant Burkitt lymphoma 18 years after renal transplantation. Following diagnosis, the patient was switched to everolimus therapy and achieved a complete response after treatment with rituximab and chemotherapy. The patient has been in remission without further treatment for seven years. This case illustrates that post-transplant lymphoproliferative disorder can occur many years after transplantation, emphasizing the need for long-term vigilance in patients. The transition to sirolimus/everolimus, along with treatment protocols involving rituximab and multiple chemotherapy agents, can achieve a complete response and sustain it for extended periods for post-transplant Burkitt lymphoma.

Publication Details

Journal
Dialnet (Universidad de la Rioja)
Published
2025-01-01
Primary Topic
Viral-associated cancers and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A rare case of very late onset post-transplant Burkitt lymphoma

Dialnet (Universidad de la Rioja)
Viral-associated cancers and disorders
article

A rare case of very late onset post-transplant Burkitt lymphoma

article en

Abstract

Post-transplant lymphoproliferative disorder typically manifests within the first year after solid organ transplantation, though it can rarely occur ten years or more post-transplant. Post-transplant Burkitt lymphoma is seldom seen following solid organ transplantation and represents an aggressive subtype. Treatment involves reducing immunosuppressive therapy alongside rituximab and the use of multiple chemotherapy agents.Our case involves a rare occurrence of post-transplant Burkitt lymphoma 18 years after renal transplantation. Following diagnosis, the patient was switched to everolimus therapy and achieved a complete response after treatment with rituximab and chemotherapy. The patient has been in remission without further treatment for seven years. This case illustrates that post-transplant lymphoproliferative disorder can occur many years after transplantation, emphasizing the need for long-term vigilance in patients. The transition to sirolimus/everolimus, along with treatment protocols involving rituximab and multiple chemotherapy agents, can achieve a complete response and sustain it for extended periods for post-transplant Burkitt lymphoma.

Dialnet (Universidad de la Rioja)
Openalex Percentile: Top 38%
Viral-associated cancers and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A rare case of very late onset post-transplant Burkitt lymphoma · Dialnet (Universidad de la Rioja) (2025) | TGRS Research Map | TGRS